微免疫治疗药物2LARTH®可在体内减轻类风湿关节炎的炎症和症状。

IF 2.3 Q2 RHEUMATOLOGY International Journal of Rheumatology Pub Date : 2020-01-23 eCollection Date: 2020-01-01 DOI:10.1155/2020/1594573
Ilaria Floris, Víctor García-González, Belen Palomares, Kurt Appel, Beatrice Lejeune
{"title":"微免疫治疗药物2LARTH®可在体内减轻类风湿关节炎的炎症和症状。","authors":"Ilaria Floris,&nbsp;Víctor García-González,&nbsp;Belen Palomares,&nbsp;Kurt Appel,&nbsp;Beatrice Lejeune","doi":"10.1155/2020/1594573","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which can cause cartilage and bone damages as well as pain and disability. In order to prevent disease progression, reduce pain, and major symptoms of RA, one good strategy consists in targeting proinflammatory cytokines that have the key role in the vicious circle of synovial inflammation and pain. The micro-immunotherapy medicine (MIM) 2LARTH® targets cytokines involved in inflammation.</p><p><strong>Aim: </strong>The aim of the study is to evaluate the effect of the MIM compared to vehicle in an <i>in vivo</i> model of RA, induced in mice after immunization with articular bovine type II collagen.</p><p><strong>Methods: </strong>Vehicle and MIM were dissolved in pure water (1 capsule in 100 ml) and 100 <i>µ</i>l was given by gavage daily for 14 days. To evaluate the severity of arthritis, wrist and ankle thickness was determined, paw edema was measured, and a clinical score from 0 to 4 was established. Furthermore, histological analysis was performed. To evaluate systemic inflammation, circulating levels of IL-1<i>β</i> and TNF-<i>α</i> were measured by ELISA.</p><p><strong>Results: </strong>Ankle thickness was found to be significantly reduced in MIM-treated mice compared to vehicle-treated mice (<i>P</i> < 0.05) and compared to untreated me (<i>P</i> < 0.05) and compared to untreated me (<i>P</i> < 0.05) and compared to untreated me (<i>β</i> and TNF-<i>α</i> were measured by ELISA. <i>P</i> < 0.05) and compared to untreated me (.</p><p><strong>Conclusion: </strong>The results indicate that the tested medicine reduces inflammation, histological, and clinical signs of RA in a CIA model.</p>","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2020-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1594573","citationCount":"13","resultStr":"{\"title\":\"The Micro-Immunotherapy Medicine 2LARTH® Reduces Inflammation and Symptoms of Rheumatoid Arthritis <i>In Vivo</i>.\",\"authors\":\"Ilaria Floris,&nbsp;Víctor García-González,&nbsp;Belen Palomares,&nbsp;Kurt Appel,&nbsp;Beatrice Lejeune\",\"doi\":\"10.1155/2020/1594573\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which can cause cartilage and bone damages as well as pain and disability. In order to prevent disease progression, reduce pain, and major symptoms of RA, one good strategy consists in targeting proinflammatory cytokines that have the key role in the vicious circle of synovial inflammation and pain. The micro-immunotherapy medicine (MIM) 2LARTH® targets cytokines involved in inflammation.</p><p><strong>Aim: </strong>The aim of the study is to evaluate the effect of the MIM compared to vehicle in an <i>in vivo</i> model of RA, induced in mice after immunization with articular bovine type II collagen.</p><p><strong>Methods: </strong>Vehicle and MIM were dissolved in pure water (1 capsule in 100 ml) and 100 <i>µ</i>l was given by gavage daily for 14 days. To evaluate the severity of arthritis, wrist and ankle thickness was determined, paw edema was measured, and a clinical score from 0 to 4 was established. Furthermore, histological analysis was performed. To evaluate systemic inflammation, circulating levels of IL-1<i>β</i> and TNF-<i>α</i> were measured by ELISA.</p><p><strong>Results: </strong>Ankle thickness was found to be significantly reduced in MIM-treated mice compared to vehicle-treated mice (<i>P</i> < 0.05) and compared to untreated me (<i>P</i> < 0.05) and compared to untreated me (<i>P</i> < 0.05) and compared to untreated me (<i>β</i> and TNF-<i>α</i> were measured by ELISA. <i>P</i> < 0.05) and compared to untreated me (.</p><p><strong>Conclusion: </strong>The results indicate that the tested medicine reduces inflammation, histological, and clinical signs of RA in a CIA model.</p>\",\"PeriodicalId\":51715,\"journal\":{\"name\":\"International Journal of Rheumatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2020-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/1594573\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/1594573\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/1594573","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 13

摘要

背景:类风湿关节炎(RA)是一种慢性炎症性关节疾病,可导致软骨和骨骼损伤以及疼痛和残疾。为了预防疾病进展,减轻疼痛和RA的主要症状,一个好的策略是靶向促炎细胞因子,促炎细胞因子在滑膜炎症和疼痛的恶性循环中起关键作用。微免疫治疗药物(MIM) 2LARTH®靶向参与炎症的细胞因子。目的:本研究的目的是评价MIM在牛关节型胶原免疫后小鼠RA体内模型中的作用,并将其与载药进行比较。方法:将载体和MIM分别溶于纯水(1粒/ 100 ml),每天灌胃100µl,连续14 d。为了评估关节炎的严重程度,测量腕部和踝关节的厚度,测量脚掌水肿,并建立0 - 4分的临床评分。此外,进行组织学分析。采用ELISA法检测血清IL-1β和TNF-α水平,评价全身性炎症。结果:mim处理小鼠踝关节厚度与药液处理小鼠相比(P < 0.05),与未处理小鼠相比(P < 0.05),与未处理小鼠相比(P < 0.05),与未处理小鼠相比(P < 0.05),与未处理小鼠相比(ELISA法测定β和TNF-α)。P < 0.05),与未治疗组比较(P < 0.05)。结论:在CIA模型中,试验药物能减轻RA的炎症、组织学和临床症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Micro-Immunotherapy Medicine 2LARTH® Reduces Inflammation and Symptoms of Rheumatoid Arthritis In Vivo.

Background: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease, which can cause cartilage and bone damages as well as pain and disability. In order to prevent disease progression, reduce pain, and major symptoms of RA, one good strategy consists in targeting proinflammatory cytokines that have the key role in the vicious circle of synovial inflammation and pain. The micro-immunotherapy medicine (MIM) 2LARTH® targets cytokines involved in inflammation.

Aim: The aim of the study is to evaluate the effect of the MIM compared to vehicle in an in vivo model of RA, induced in mice after immunization with articular bovine type II collagen.

Methods: Vehicle and MIM were dissolved in pure water (1 capsule in 100 ml) and 100 µl was given by gavage daily for 14 days. To evaluate the severity of arthritis, wrist and ankle thickness was determined, paw edema was measured, and a clinical score from 0 to 4 was established. Furthermore, histological analysis was performed. To evaluate systemic inflammation, circulating levels of IL-1β and TNF-α were measured by ELISA.

Results: Ankle thickness was found to be significantly reduced in MIM-treated mice compared to vehicle-treated mice (P < 0.05) and compared to untreated me (P < 0.05) and compared to untreated me (P < 0.05) and compared to untreated me (β and TNF-α were measured by ELISA. P < 0.05) and compared to untreated me (.

Conclusion: The results indicate that the tested medicine reduces inflammation, histological, and clinical signs of RA in a CIA model.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
9
审稿时长
24 weeks
期刊最新文献
An Observational Study on the Clinical Characteristics and Prognosis of Patients With Interstitial Lung Disease Secondary to Dermatomyositis and Antisynthetase Syndrome. Exploring the Psychiatric Manifestations of Primary Sjögren’s Syndrome: A Narrative Review Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy. Primary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities Association of Cytokine IL-17, IL-4, IL-6, and IL-12 Gene Polymorphisms in Rheumatoid Arthritis Patients in a Tertiary Care Hospital in Bangladesh.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1